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Abstract
Background: The serine/threonine kinase PAK1 is an important regulator of cell motility. Both PAK1 and the
hormone/cytokine prolactin (PRL) have been implicated in breast cancer cell motility, however, the exact
mechanisms guiding PRL/PAK1 signaling in breast cancer cells have not been fully elucidated. Our lab has
previously demonstrated that PRL-activated tyrosine kinase JAK2 phosphorylates PAK1 on tyrosines 153, 201, and
285, and that tyrosyl phosphorylated PAK1 (pTyr-PAK1) augments migration and invasion of breast cancer cells.
Results: Here we further investigate the mechanisms by which pTyr-PAK1 enhances breast cancer cell motility in
response to PRL. We demonstrate a distinct reduction in PRL-induced FAK auto-phosphorylation in T47D and
TMX2-28 breast cancer cells overexpressing wild-type PAK1 (PAK1 WT) when compared to cells overexpressing
either GFP or phospho-tyrosine-deficient mutant PAK1 (PAK1 Y3F). Furthermore, pTyr-PAK1 phosphorylates MEK1 on
Ser298 resulting in subsequent ERK1/2 activation. PRL-induced FAK auto-phosphorylation is rescued in PAK1 WT
cells by inhibiting tyrosine phosphatases and tyrosine phosphatase inhibition abrogates cell motility and invasion in
response to PRL. siRNA-mediated knockdown of the tyrosine phosphatase PTP-PEST rescues FAK auto-
phosphorylation in PAK1 WT cells and reduces both cell motility and invasion. Finally, we provide evidence that
PRL-induced pTyr-PAK1 stimulates tumor cell metastasis in vivo.
Conclusion: These data provide insight into the mechanisms guiding PRL-mediated breast cancer cell motility and
invasion and highlight a significant role for pTyr-PAK1 in breast cancer metastasis.
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Background
Prolactin (PRL) is a peptide hormone/cytokine that is
typically secreted from the anterior pituitary gland, and
has been found to be locally produced in various other
organs such as the prostate, uterus, and mammary gland
(for review [1]). Upon PRL binding, PRL-receptor (PRLR)
dimerizes resulting in activation of the non-receptor
tyrosine kinase JAK2 (Janus kinase 2) and subsequent
downstream signaling cascades including signal trandu-
cers and activators of transcription (STATs), mitogen acti-
vated protein kinases (MAPKs), including ERK1/2, and
phosphoinositol-3 kinase pathways (for review [2]). PRL
signaling at both an endocrine and paracrine/autocrine
levels regulates a variety of physiological processes in an
eclectic range of tissues (for review [3]). There is mount-
ing evidence that PRL plays a significant role in breast
cancer. The PRLR has been found in the vast majority of
human breast cancers and PRL signaling has been impli-
cated in breast cancer cell proliferation, survival, motility
and angiogenesis (for review [2]). Furthermore, elevated
circulating PRL levels have been positively correlated with
breast cancer metastasis and PRLR-deficient mice have
prevention of neoplasia progression into invasive carcin-
oma [4–7]. Importantly, PRL has been noted as a chemo-
attractant for breast cancer cells and augments tumor
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metastasis in nude mice [8, 9]. However, the exact mecha-
nisms guiding PRL-induced cell migration and tumor me-
tastasis are not fully understood.
We have implicated the serine/threonine kinase PAK1
(p21-activated kinase-1) as a substrate of PRL-activated
JAK2 [10]. PAK1 has been associated with breast cancer
progression (for review [11]). Aberrant expression/acti-
vation of PAK1 has been described in breast cancer as
well as among several other cancers including brain,
pancreas, colon, bladder, ovarian, hepatocellular, urinary
tract, renal cell carcinoma, and thyroid cancers (for review
[12]). The PAK1 gene lies within the 11q13 region and
11q13.5→ 11q14 amplifications involving the PAK1 locus
are present in 17 % of breast cancers [13, 14]. PAK1 over-
expression was observed in over half of observed breast
tumor specimens [15] and PAK1 expression is correlated
with tumor grade [16–18]. In transgenic mouse models,
hyperactivation of PAK1 promotes mammary gland tumor
formation [19]. Interestingly, overexpression of constitu-
tively active PAK1 T423E in non-invasive breast cancer
cells stimulates cell motility and anchorage independence
[17], while expression of kinase dead PAK in highly inva-
sive breast cancer cells significantly reduces cell invasive-
ness [20]. PAK1 kinase activity promotes directional cell
motility and is a major regulator of the actin cytoskeleton
(for review [11]). We have previously demonstrated that
PRL-activated JAK2 directly phosphorylates PAK1 on ty-
rosines 153, 201, and 285 [10]. We have also demon-
strated that tyrosyl phosphorylated PAK1 (pTyr-PAK1)
enhances PRL-mediated cell invasion via MAPK activation
and increased matrix metalloproteinase expression [21] as
well as cell motility through increased phosphorylation of
actin-crosslinking protein filamin A ([22]; reviewed in
[23]). Additionally, PRL-induced pTyr-PAK1 is localized
at small adhesion complexes at the cell periphery and reg-
ulates adhesion turnover in breast cancer cells, a process
that is absolutely critical for cell motility [24].
Cell motility is essential in the regulation of many sig-
nificant biological processes including embryogenesis,
wound healing, and immune responses; however aberrant
cell migration is present in malignant cancers and results
in the establishment of tumors in distant tissues. Cell mo-
tility is a highly coordinated process that requires tight
regulation of the actin cytoskeleton, cell-matrix adhesion
turnover, and complex intracellular signaling cascades.
The tyrosine kinase focal adhesion kinase (FAK) has been
implicated as an important regulator of cell motility (for
review [25]). FAK is localized to cell/matrix adhesions and
is activated by integrin engagement to the extracellular
matrix as well as by several other extracellular ligands (for
review [26]). Auto-phosphorylation of FAK at tyrosine 397
(Y397) promotes FAK activation and recruits SH2- and
SH3-domain containing proteins, most notably c-Src,
leading to Src-mediated FAK activation and activation of
Src/FAK signaling pathways, including the ERK MAPK
signaling cascade (for review [26]). FAK activation has
been most well implicated in the positive regulation of cell
motility (for review [26, 27]). However, recently more evi-
dence has demonstrated a controversial role for FAK as a
negative regulator of cancer cell migration [28–30].
Here we extend our knowledge on the role for
pTyr-PAK1 in PRL-induced breast cancer cell motility
and invasion. We use T47D and TMX2-28 breast cancer
cells stably overexpressing GFP, PAK1 WT, or tyrosyl
phosphorylation-deficient mutant of PAK1 in which the
three JAK2 phosphorylation sites have been mutated to
phenylalanine (PAK1 Y3F). These cells were previously
characterized in [22, 24] and [21]. We demonstrate here
that tyrosyl phosphorylation of PAK1 in response to PRL
regulates PTP-PEST-dependent FAK dephosphorylation,
resulting in augmented breast cancer cell migration and
invasion and proposed the mechanism explaining these
findings. Furthermore, we provide in vivo evidence that
PRL-induced pTyr-PAK1 increases breast cancer cell
metastasis. Taken together, these data suggest that
PRL-mediated pTyr-PAK1 is important in regulating
the dynamic activation of FAK and subsequent breast
cancer cell migration and invasion.
Methods
Antibodies and reagents
Polyclonal αpY397-FAK (Abcam), monoclonal αFAK
(EMD Millipore), polyclonal αpS298-MEK (Cell Signaling),
monoclonal αMEK (GeneTex), monoclonal αphospho-
ERK1/2 (pT202/Y204) and polyclonal αERK1/2 (Cell
Signaling), monoclonal αmyc (9E10, Santa Cruz Biotech-
nology), and αγ-tubulin (Sigma-Aldrich) were used for
immunoblotting. Na3VO4 was purchased from Sigma.
siRNA and primers for PTP-PEST were purchased from
Santa Cruz Biotechnology. Control nontargeting siRNA
was purchased from Cell Signaling. Human PRL was pur-
chased from the National Hormone and Peptide Program
(Dr. Parlow, National Institute of Diabetes and Digestive
and Kidney Diseases).
Cell culture
Prolactin receptor- and estrogen receptor-positive T47D
cells stably overexpressing GFP, myc-tagged PAK1 WT,
and myc-tagged PAK1 Y3F were described previously
[22, 24]. T47D clones were maintained in RPMI 1640
medium (Corning Cellgro, Corning, Inc) supplemented
with 10 % fetal bovine serum (FBS; Sigma-Aldrich) and
insulin (Sigma-Aldrich). Prolactin receptor-positive but
estrogen receptor-negative TMX2-28 cells (a variant of
the MCF-7 breast cancer cell line [31]) and their clones
stably overexpressing GFP, PAK1 WT or PAK1 Y3F were
described previously [21] and maintained in DMEM
supplemented with 10 % fetal bovine serum. The levels
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of overexpressed PAK1 WT and PAK1 Y3F were roughly
estimated to be around 20-fold over the level of endogen-
ous PAK1 in both T47D cells and TMX2-28 cells. MCF-7
cells were kindly donated by Dr. Ethier (University of
Michigan) and T47D cells were purchased from the
ATCC. TMX2-28 cells were kindly donated by Dr. Eisen-
mann (University of Toledo, OH).
Assessing FAK, MEK, and ERK phosphorylation
T47D or TMX2-28 clones were seeded into 6-well
dishes and deprived of serum for 72 h before treatment
with or without PRL (200 ng/ml) for the indicated times.
Cells were lysed and proteins were resolved by SDS-
PAGE followed by immunoblotting with the indicated
antibodies. Fold FAK, MEK, and ERK activation was
assessed by densitometric analysis of αphospho-protein
bands normalized to αtotal-protein bands using ImageJ
software. To assess FAK activation in T47D clones in
the absence of tyrosine phosphatase activity, cells were
treated with 100 ng/ml of Na3VO4 for one hour before
treatment with or without PRL (200 ng/ml) for the indi-
cated times. Cells were lysed and proteins were resolved
by SDS-PAGE followed by immunoblotting with the in-
dicated antibodies. FAK activation was assessed by
densitometric analysis of αpY397-FAK bands normalized
to αFAK bands using ImageJ software.
PTP-PEST knockdown
PTP-PEST siRNA or control nontargeting siRNA were
transfected into T47D or TMX2-28 cells using Lipofecta-
mine RNAiMAX (Invitrogen) according to the manufac-
turer’s instructions. The final concentration of the siRNA
was 100 nM. Knockdown of PTP-PEST mRNA was
assessed by RT-PCR method using PTP-PEST primers.
To assess PRL-induced FAK activation in the absence
of PTP-PEST, T47D and TMX2-28 clones were transfected
with PTP-PEST siRNA, deprived of serum for 48 h, and
treated with or without PRL for the indicated times. Cells
were lysed and proteins were resolved by SDS-PAGE
followed by immunoblotting with the indicated antibodies.
Cell viability
To assess cell viability in the presence of 100 ng/ml
Na3VO4 for 48 h, equal numbers of T47D cells were re-
suspended in deprivation media (RPMI 1640 medium
supplemented with 1 % BSA) with or without PRL
(200 ng/ml) and Na3VO4 (100 ng/ml) then seeded into a
96-well plate. After 48 h, cells were subjected to the
Vybrant® MTT Cell Proliferation Assay (Molecular Probes)
according to the manufacturer’s instructions.
Cell migration and cell invasion assays
Cell migration and cell invasion assays were performed
as we described previously [21, 22]. Equal cell numbers of
the T47D (1 × 106 cells/chamber) or TMX2-28 (0.5 × 106
cells/chamber) stable cell lines for each condition were
placed in deprivation media with or without 100 ng/ml
Na3VO4 in the upper chamber of a Boyden chamber
(8.0 μm pores, Corning, Inc) (migration assay) or a
Boyden chamber (8.0 μm pores), coated with Matrigel
(BD Biosciences) (invasion assay). Deprivation media with
or without 200 ng/ml PRL was placed in the lower cham-
ber. Cells were allowed to migrate or invade for 48 h, after
which the cells remaining in the upper chamber were re-
moved from the upper chamber by a cotton swab. Cells
from five separate fields that had migrated through the
pores of the membrane to the underside of the filter were
counted after fixation with 4 % formalin (Sigma) and
staining with Differential Quik Stain (Polysciences, Inc).
Brightfield images of migrated/invaded cells were acquired
on an inverted Olympus IX81 microscope using LUCPlan
FLN 40× objective lens and wide field WHN 10X eyepiece
(Olympus, Tokyo, Japan).
To assess the effect of PTP-PEST knockdown on cell
migration and invasion, T47D and TMX2-28 stable clones
were transfected with PTP-PEST siRNA. After 24 h,
cells were placed in deprivation media in the upper
chamber of a Boyden chamber (migration assay) or a
Boyden chamber coated with Matrigel (invasion assay).
Cells were allowed to migrate/invade for 48 h and proc-
essed as described above.
In vivo metastasis
TMX2-28 clones stably overexpressing GFP, myc-PAK1
WT or myc-PAK1 Y3F were inoculated directly into mam-
mary fat pad of NSG (NOD/SCID/ IL2Rgamma) female
mice. hPRL (20 μg/100 μl) was injected subcutaneously
every other day for 8 weeks and mice were terminated in
12 weeks. 8 mice were used for TMX2-28 PAK1 clone, 6
mice for TMX2-28 PAK1 Y3F clone and 4 mice for
TMX2-28 GFP clone. Mouse experimental procedures
were performed in the animal research core of Lerner Re-
search Institute, Cleveland Clinic (Dr. Lindner), and were
approved by the Institutional Animal Care and Use Com-
mittee, Cleveland Clinic. The first half of tumors and lungs
from mice was frozen and kept at −80 °C. Before use, the
tissues were homogenized in RIPA buffer with protease in-
hibitors (50 mM Tris-HCl, 150 mM NaCl, 2 nM EGTA,
1 % Triton X-100, aprotinin 10 μg/ml, leupeptin, 10 μg/ml,
pH7.5; 500 μL per 10 mg tissue) at 4 °C. Homogenized tis-
sues were rotated in RIPA buffer for 1 h at 4 °C to ensure
cell lysis. Samples were centrifuged at 10,000 g to pellet
debris and protein concentration in supernatant was deter-
mined by Bradford assay. Proteins were separated by SDS-
PAGE and transferred to PVDF membrane. Lysates of
TMX2-28 PAK1 WT cells were loaded as a control for
PAK1-myc position in the gels. Membranes were probed
with anti-myc to detect myc-PAK1 WT or Y3F in the
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tissues and anti-tubulin for loading control. The second
half of tumors and lungs was fixed with 10 % formalin and
embedded in paraffin. Immunohistochemistry using
paraffin-embedded sections was done as described previ-
ously [24]. Briefly, formalin-fixed, paraffin-embedded sec-
tions were boiled for 15 min in 0.01 M sodium citrate
buffer (pH 6.0) to expose antigenic epitopes. Sections were
blocked with 2.5 % normal horse serum for 30 min and
then incubated overnight with anti-myc (1:100) or control
pre-immune serum. The biotinylated secondary antibody
was used followed by streptavidin horseradish peroxidase
solution (R.T.U. Vectstatin universal quick kit, Vector La-
boratories). The chromogen was 3,3’ diaminobenzidine
(ImmPACT DAB kit, Vector Laboratories). Staining with
pre-immune serum was negligible (not shown).
Statistical analysis
Data from at least 3 separate experiments were pooled
and analyzed using 1-way ANOVA plus Tukey’s honest
significant difference test. Differences were considered to
be statistically significant at P < 0.05. Results are expressed
as the mean ± SE.
Results
Tyrosyl phosphorylated PAK1 negatively regulates FAK
auto-phosphorylation
We have previously demonstrated that PRL promotes
breast cancer cell motility in a pTyr-PAK1-dependent
manner [22]. In an attempt to understand the pTyr-PAK1-
dependent mechanism that regulates PRL-induced cell
motility, we first examined the auto-phosphorylation of
FAK in response to PRL, as FAK is an important regulator
of cell motility (for review [25]). T47D GFP (control),
PAK1 WT, or PAK1 Y3F (phospho-tyrosine-deficient mu-
tant) clones were treated with PRL over a time-course and
whole cell lysates (WCL) were analyzed for FAK auto-
phosphorylation at Y397, which is critical for Src/FAK
interaction and maximal FAK activation (reviewed in [32]).
PRL treatment led to maximal FAK auto-phosphorylation
in 15 min in control GFP cells (Fig. 1a, left blot; Fig. 1b,
solid line). On the contrary, there was no significant
Y397-FAK auto-phosphorylation in response to PRL in
the PAK1 WT cells (Fig. 1a, middle blot; Fig. 1b, dashed
line), suggesting that PRL-induced pTyr-PAK1 has a
negative effect on FAK auto-phosphorylation. FAK was
maximally auto-phosphorylated by PRL in 7.5 min in
PAK1 Y3F cells (Fig. 1a, right blot; Fig. 1b, dotted line).
Similar results were obtained in TMX2-28 (estrogen-re-
ceptor-negative sub-line of the MCF-7 breast cancer cells
[31]) stably overexpressing GFP, myc-PAK1 WT, or myc-
PAK1 Y3F (Fig. 2d, anti-pY397-FAK and anti-FAK blots)
indicating that this finding was not restricted to T47D
cells. It is important to note that PRL-dependent Y395-
FAK phosphorylation was transient in both T47D GFP
and T47D PAK1 Y3F clones. Our data suggest that tyrosyl
phosphorylation of PAK1 in response to PRL promotes
FAK dephosphorylation and tyrosines 153, 201 and 285 of
PAK1 are responsible for this effect.
Fig. 1 Tyrosyl phosphorylation of PAK1 negatively regulates PRL-induced FAK auto-phosphorylation. a Whole cell lysates (WCL) of T47D cells
stably overexpressing GFP, PAK1 WT, or PAK1 Y3F treated with PRL (200 ng/ml) for the indicated times were probed for FAK auto-phosphorylation
using αpY397-FAK antibody. The expression levels of γtubulin were used as an internal loading control. b Graph represents the densitometric analysis
of the bands obtained for pY397-FAK normalized to total FAK for at least 3 independent experiments. The solid line represents T47D GFP cells, the
dashed line represents T47D PAK1 WT cells, and the dotted line represents T47D PAK1 Y3F cells. Bars represent mean ± SE. *P < 0.05 compared with
the same cells not treated with PRL
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Tyrosyl phosphorylation of PAK1 promotes S298-MEK1
phosphorylation and ERK activation in response to PRL
To uncover the mechanism by which pTyr-PAK1 may
regulate FAK phosphorylation, we assessed S298-MEK
phosphorylation and consequent ERK1/2 activation
(dual phosphorylation of T202 and Y204 of ERK1/2 me-
diates ERK activity [33, 34]) in response to PRL because
a PAK1/MEK/ERK signaling cascade has been impli-
cated in Ras-mediated FAK dephosphorylation [30]. PRL
promoted PAK1-dependent MEK phosphorylation 6-fold
in as early as 7.5 min and maximal 8-fold MEK phos-
phorylation after 15 min in T47D PAK1 WT cells
(Fig. 2a, middle blot, Fig. 2b). PRL also induced pS298-
MEK signal in the T47D GFP and T47D PAK1 Y3F cells
albeit slower and to a lesser extent when compared to
the PAK1 WT cells (Fig. 2a, left and right blots, Fig. 2b).
Subsequently, ERK1/2 was phosphorylated in response
to PRL in all three T47D clones, however earlier and to
a much greater extent in the PAK1 WT cells when com-
pared to GFP and PAK1 Y3F cells (Fig. 2a and c). Similar
results were obtained in TMX2-28 GFP, PAK1 WT and
PAK1 Y3F cell clones (Fig. 2d, anti-pS298-MEK, anti-p-
ERK1/2, anti-MEK and anti-ERK1/2 blots). These data
suggest that PAK1 tyrosyl phosphorylation promotes
PAK-dependent MEK phosphorylation and ERK activa-
tion in response to PRL.
Fig. 2 Tyrosyl phosphorylation of PAK1 promotes S298-MEK1 phosphorylation and ERK activation in response to PRL. a WCL of T47D cells stably
overexpressing GFP, PAK1 WT, or PAK1 Y3F treated with PRL (200 ng/ml) for the indicated times were probed for MEK phosphorylation using
αpS298-MEK and ERK1/2 activation using αphospho-ERK1/2 (pT202/Y204) antibodies. b, c Graphs represent the densitometric analysis of the
bands obtained for phospho-MEK (b) or phospho-ERK1/2 (c) normalized to total MEK or ERK1/2, respectively, for at least 3 independent
experiments. Bars represent mean ± SE . *P < 0.05 compared with cells expressing GFP with the same treatment. d WCL of TMX2-28 cells
stably overexpressing GFP, PAK1 WT, or PAK1 Y3F treated with PRL (200 ng/ml) for the indicated times were probed with the indicated antibodies. The
expression levels of γtubulin were used as an internal loading control
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Protein tyrosine phosphatase inhibition rescues
PRL-mediated auto-phosphorylation of FAK
In order to determine whether tyrosine phosphatases are
involved in the negative effect of pTyr-PAK1 on FAK
auto-phosphorylation, we assessed Y397- FAK phos-
phorylation in response to PRL in the presence or ab-
sence of Na3VO4, a tyrosine phosphatase inhibitor.
T47D PAK1 WT cells were treated with vehicle or
Na3VO4 for one hour before PRL treatment and WCL
were assessed for pY397-FAK (Fig. 3). As expected,
there was no PRL-mediated increase in FAK tyrosyl
phosphorylation in vehicle treated cells (Fig. 3a, lanes 1
and 2). However, phosphatase inhibition led to a signifi-
cant increase in both basal and PRL-induced FAK auto-
phosphorylation (Fig. 3a, lanes 3 vs. 1 and 4 vs. 2). To
confirm that phosphatase activity is important for the
pTyr-PAK1-dependent effect of PRL on FAK dephos-
phorylation, all three T47D clones were subjected to a
PRL time-course in the presence of Na3VO4 and WCL
were assessed for Y397 FAK auto-phosphorylation
(Fig. 3b, c). In the presence of Na3VO4, PRL treatment
activated FAK in all three cell lines regardless of the
status of PAK1 tyrosyl phosphorylation (Fig. 3b, c). Fur-
thermore, FAK remained phosphorylated until the end
of the PRL time-course in all three clones in the pres-
ence of Na3VO4.
Next we aimed to determine whether tyrosine phos-
phatase PTP-PEST, which dephosphorylates FAK at Y397
[30], participates in PRL- and PAK1-dependent lack of
FAK auto-phosphorylation. PTP-PEST silencing in T47D
and TMX2-28 clones was confirmed by RT-PCR method
(Fig. 4a). We performed siRNA-based silencing of PTP-
PEST in T47D (Fig. 4b) and TMX2-28 (Fig. 4c) clones,
treated the cells with or without PRL and assessed for
Y397 FAK auto-phosphorylation. Indeed, PTP-PEST silen-
cing rescued Y397-FAK phosphorylation in PAK1 WT
cells to similar levels to that of GFP and PAK1 Y3F cells in
response to PRL (Fig. 4b, c). On the contrary, there was no
significant Y397-FAK auto-phosphorylation in response to
PRL in the PAK1 WT clones transfected with control
siRNA (Fig. 4b, c).
These data suggest that tyrosine phosphatase activ-
ity of PTP-PEST is responsible for the apparent lack
of FAK auto-phosphorylation in response to PRL in
PAK1 WT cells. Given the complexity of these sig-
naling cascades, it is likely that additional signaling
molecules are also involved in the modulation of FAK
phosphorylation.
Fig. 3 Protein tyrosine phosphatase inhibition rescues PRL-mediated FAK auto-phosphorylation in T47D WT cells. a Tyrosine phosphatase inhibition by
Na3VO4 permits PRL-induced FAK auto-phosphorylation in PAK1 WT cells. WCL of T47D PAK1 WT cells treated with either vehicle (veh) or
Na3VO4 (100 ng/ml) for 1 h before PRL (200 ng/ml) treatment were probed for FAK auto-phosphorylation by αpY397-FAK antibody. b FAK
is auto-phosphorylation in T47D GFP, PAK1 WT, and PAK1 Y3F cells in response to PRL in the presence of Na3VO4. The cells were treated
with Na3VO4 as in A and with PRL (200 ng/ml) for the indicated times. FAK auto-phosphorylation was assessed as in A. The expression levels of γtubulin
were used as an internal loading control. c Graph represents the densitometric analysis of the bands obtained for pY397-FAK normalized to total FAK
for at least 3 independent experiments. Bars represent mean ± SE. *P < 0.05 compared with the same cells not treated with PRL
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Protein tyrosine phosphatase inhibition impedes PRL-
mediated T47D and TMX2-28 cell migration and invasion
To investigate whether tyrosine phosphatases regulate
PRL/pTyr-PAK1-dependent T47D breast cancer cell mi-
gration, we examined migration of T47D clones in the
presence and absence of PRL and Na3VO4 for 48 h. As
dynamic tyrosyl phosphorylation events are crucial to
many cellular processes, it was important to test whether
phosphatase inhibition for an extended period of 48 h
had any cytotoxic effect. The cell viability was assessed
in serum deprived T47D cells treated with or without
PRL and Na3VO4 (Fig. 5c). Na3VO4 had no significant
cytotoxic effect on any of the three stable cell lines in
the presence or absence of PRL (Fig. 5c). Next, the effect
of tyrosine phosphatase inhibition on PRL-mediated cell
migration was assessed using a transwell migration assay.
Equal numbers of T47D GFP, PAK1 WT and PAK1 Y3F
cells were seeded into the upper part of a Boyden chamber
with or without Na3VO4 and PRL or vehicle were added
to the bottom part. The number cells that migrated
through the chamber towards PRL were counted (Figs. 5a
and d). As we demonstrated previously [22], PRL stimu-
lated cell migration to a greater extent in PAK1 WT cells
when compared to GFP and PAK1 Y3F cells in the ab-
sence of Na3VO4 (Fig. 5d, veh). However, phosphatase in-
hibition by Na3VO4 completely abolished cell migration in
response to PRL in all T47D clones (Fig. 5d, Na3VO4).
These data suggest that phosphatase activity is required
for pTyr-PAK1-induced cell migration.
Cell migration is a key step in cell invasion so we de-
cided to assess the effect of phosphatase inhibition on
cell invasion. Equal numbers of T47D GFP, PAK1 WT
and PAK1 Y3F cells were seeded into the upper chamber
of a Boyden chamber coated with Matrigel, in the pres-
ence of either Na3VO4 or vehicle. Deprivation media with
or without PRL (200 ng/ml) was added to the lower cham-
ber of the Boyden chamber. The number of cells that
invaded through the Matrigel towards PRL was counted.
As we demonstrated previously [21], PRL stimulated cell
invasion to a greater extent in PAK1 WT cells when com-
pared to GFP and PAK1 Y3F cells in the absence of
Na3VO4 (Fig. 5b and e, veh). However, Na3VO4-mediated
tyrosine phosphatase inhibition abolished cell invasion in
response to PRL in all T47D clones (Fig. 5e, Na3VO4).
To demonstrate that the role of PAK1 in PRL-mediated
signaling is not limited to T47D cells, we assessed migra-
tion and invasion in the presence and absence of Na3VO4
in TMX2-28 clones. In TMX2-28 GFP and TMX2-28 WT
cells PRL induced cell migration (Fig. 6a, veh) and inva-
sion (Fig. 6b, veh) while in TMX2-28 Y3F cells did not
(Fig. 6a and b, veh). However, Na3VO4 treatment abol-
ished PRL-dependent cell migration and invasion in all
TMX2-28 clones (Fig. 6a and b, Na3VO4). Silencing of
PTP-PEST also abolished PRL-dependent cell migration
and invasion of all T47D clones (Fig. 6c and d) and migra-
tion of TMX2-28 clones (Fig. 6e). PRL-induced invasion
of TMX2-28 control (GFP) and WT cells was significantly
decreased by silencing of PTP-PEST although not com-
pletely abolished (Fig. 6f) suggesting that, in addition to
PTP-PEST, other tyrosine phosphatases may participate in
the pTyr-PAK1-dependent invasion of TMX2-28 cells.
PAK1 tyrosyl phosphorylation stimulates PRL-induced
tumor metastasis in vivo
Cell migration is critical for tumor cell metastasis. In
order to assess whether PRL-induced tyrosyl phosphoryl-
ation of PAK1 has a physiological effect on breast cancer
Fig. 4 Silencing of tyrosine phosphatase PTP-PEST rescues FAK
auto-phosphorylation in T47D and TMX2-28 cells. a PTP-PEST siRNA
reduces PTP-PEST mRNA in T47D and TMX2-28 cells. T47D and TMX2-
28 cells were transfected with either PTP-PEST siRNA or control
non-coding siRNA (ctrl) and mRNA levels were assessed by RT-PCR
using PTP-PEST-specific primers. GAPDH primers were used an internal
control. b WCL of T47D and TMX2-28 clones transfected with control
or PTP-PEST siRNAs and treated with PRL (200 ng/ml) for 0 or 15 min
were probed for FAK auto-phosphorylation using αpY397-FAK
antibody. The expression levels of γtubulin were used as an internal
loading control. c Graph represents the densitometric analysis of the
bands obtained for pY397-FAK normalized to total FAK
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metastasis, TMX2-28 stably overexpressing GFP, myc-
PAK1 WT, or myc-PAK1 Y3F were inoculated in mouse
mammary fat pads and mice were treated with PRL for
8 weeks. Tumors and lungs were harvested and homoge-
nized and proteins were separated by SDS-PAGE and ana-
lyzed for myc-tagged PAK1 to indicate metastasis of the
primary tumor into distant tissues. We focused on the pri-
mary tumor and the lungs, as the lungs are one of the
most common sites for secondary tumor in patients with
metastatic breast cancer. As expected, each primary tumor
from all PAK1 WT and PAK1 Y3F mice was positive for
myc-tagged PAK1 (Fig. 7a) while GFP cells do not produce
tumors. Myc-tagged PAK1 was detected in 3 out of 8
lungs from the PAK1 WT mice while there was no detect-
able myc-PAK1 in any of the PAK1 Y3F or GFP mouse
lungs (Fig. 7a). Tumors and lungs were also fixed and ana-
lyzed by immunocytochemistry (IHC) with anti-myc. Our
IHC analysis revealed that anti-myc signal was detected in
breast tumor (B) of myc-PAK1 WT- and myc-PAK1 Y3F-
inoculated mice (C) as well as in lung of myc-PAK1 WT-
Fig. 5 Protein tyrosine phosphatase inhibition impedes PRL-mediated T47D cell migration and invasion. a, b Equal amounts of T47D GFP, PAK
WT, or PAK1 Y3F cells were loaded into the upper part of the Boyden chamber uncovered (a) or covered with Matrigel (b) with or without Na3VO4
(100 ng/ml). PRL (200 ng/ml) was added to the lower part. Representative brightfield images of the cells migrated/invaded to the lower chamber
were taken in 48 h. A LUCPlan FLN 40X objective lens and wide field WHN 10X eyepiece on an inverted Olympus IX81 microscope were used.
(c) Na3VO4 (100 ng/ml) treatment on T47D cells for 48 h has no cytotoxic effect. d, e The number of cells that migrated to the lower surface of the
chamber toward PRL (white bar) or vehicle (black bar) after 48 h was counted and plotted. Bars represent mean ± SE. *P < 0.05 compared with the
same cells not treated with PRL
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inoculated mice (D) but not in lungs of control GFP- (E)
or PAK1 Y3F-inoculated mice (F). These data provide first
in vivo evidence that tyrosyl phosphorylation of PAK1
plays a significant role in PRL-induced breast cancer cell
motility and metastasis, as only cells overexpressing PAK1
WT, but not phospho-tyrosine-deficient PAK1 Y3F, were
able to migrate from the primary tumor to the lungs. Here
we provide new insight into the mechanisms regulating
PRL-dependent breast cancer cell metastasis.
Discussion
The role of PAK1 in the regulation of cell motility is well
documented (reviewed in [11]). The role of PAK1 in the
regulation of cell adhesion is also well documented and at
least one mechanism has been proposed ([35], reviewed in
[36]). According to this mechanism, PAK1 phosphorylates
paxillin on Ser273, leading to increased paxillin-GIT1
binding and adhesion turnover [35]. We have previously
implicated PRL/JAK2-dependent tyrosyl phosphorylation
of PAK1 in regulation of cell motility and invasion
[21, 22]. We have also implicated pTyr-PAK1 in the
regulation of breast cancer cell adhesion and demon-
strated that phosphorylation of tyrsines 153, 201 and 285
of PAK1 regulates cell adhesion, contribute to maximal
PAK1 kinase activity and increased ability to bind βPIX
and GIT1 [24]. Here we extend our findings and demon-
strate that pTyr-PAK1 phosphorylates MEK1 on Ser289
resulting in subsequent ERK1/2 activation. We also show
that PRL-induced FAK auto-phosphorylation on Tyr397 is
inhibited by pTyr-PAK1 and can be rescued by inhibiting
Fig. 6 Silencing of the tyrosine phosphatase PTP-PEST reduces PRL-mediated cell migration and invasion. a Tyrosine phosphatase inhibition abolishes
PRL-induced TMX2-28 cell migration a and invasion b. TMX2-28 GFP, PAK WT, or PAK1 Y3F cells were assessed as in Fig. 5. c–f Equal amount of T47D
(c, d) or TMX2-28 (e, f) clones were transfected with either control or PTP-PEST siRNA and loaded into the upper part of the Boyden chamber covered
(d, f) or not (c, e) with Matrigel. The number of cells that migrated/invaded to the lower chamber toward PRL (white bar) or vehicle (black bar) after
48 h was counted and plotted. Bars represent mean ± SE. *P < 0.05 compared with the same cells not treated with PRL. #P < 0.05 compared with the
same cells treated with PRL but transfected with control siRNA (f)
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tyrosine phosphatases and silencing tyrosine phosphatase
PTP-PEST. These tyrosine phosphatase inhibitions ab-
rogate cell motility and invasion in response to PRL. We
hypothesize that pSer910-FAK recruits tyrosine phosphat-
ase PTP-PEST to dephosphorylate pTyr397-FAK and
thereby promotes cell motility as shown previously [30].
Dynamic of FAK phosphorylation is significant for cell
motility. Previously, FAK activation has been demon-
strated to positively regulate cell motility (for review
[25–27]) however it is becoming evident that the role of
FAK activation in cell migration is more complex. Silen-
cing FAK using siRNA enhanced HeLa cell migration on
collagen, and FAK dephosphorylation on Y397 by the
tyrosine phosphatase PTP-PEST promoted Ras-induced
cell migration in transformed NIH3T3-v-H-Ras cells
[29, 30]. Cells with reduced FAK dephosphorylation had
diminished cell motility [37] and overexpression of the
tyrosine phosphatase LMR-PTP, which dephosphorylates
FAK, enhanced cell motility [38]. Importantly, Zheng et al.
implicated PAK1 in regulation of Ras-induced FAK de-
phosphorylation, as overexpression of constitutively active
PAK1 T423E promoted FAK dephosphorylation while in-
hibition of PAK1 severely abolished FAK dephosphory-
lation at Y397 [30]. With agreement with these data, we
have shown here that pTyr-PAK1 abolished PRL-
dependent phosphorylation of Ser397-FAK.
We previously demonstrated that tyrosyl phosphoryl-
ation of PAK1 promotes both PAK1 kinase activity and
protein-protein interaction capabilities (for review [23]).
PAK1 directly binds to ERK in response to adhesion to
fibronectin, and both PAK1 and ERK co-localize at nas-
cent adhesions on the cell periphery [39]. Here, PAK1 can
serve as a scaffold, bringing together Raf, MEK and ERK
at cell/matrix adhesions and thereby stimulating ERK-
Fig. 7 PAK1 tyrosyl phosphorylation stimulates PRL-induced tumor metastasis in vivo. a myc-PAK1 was detected in all tumor lysates isolated from
myc-PAK1 WT and myc-PAK1 Y3F inoculated mice. PRL-induced tyrosyl phosphorylation of PAK1increased tumor metastasis, as 3 out of 8 lungs
from WT mice contained myc-PAK1 (lanes 2, 4 and 5). No myc-PAK1 was detected in any of the lungs from the Y3F or GFP mice. Anti-tubulin
antibody was used as a loading control. Whole cell lysate (WCL) of TMX2-28 PAK1 WT cells was loaded as a control for PAK1-myc position in the
gels. b–f Representative images of myc-PAK1 detected with anti-myc in breast tumor (b, c) and lung tissue (d–f). myc-PAK1 was detected in
breast tumors of myc-PAK1 WT- (b) and Y3F- (c) and lung of myc-PAK1 WT- inoculated mice (d) but not in lungs of GFP (e) or PAK1 Y3F-inoculated
mice (f). The arrow highlights metastatic nodule. Counterstaining with hematoxylin was omitted. Scale bar is 200 μm in (b) and 100 μm in (c–e)
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dependent signal transduction [39]. In addition to PAK1
scaffolding activity, PAK1 promotes Raf activation by dir-
ectly phosphorylated Raf on S338/339 [40, 41], and stimu-
lates MEK/ERK binding and subsequent ERK activity by
directly phosphorylating S298 on MEK1 [42–44]. Import-
antly, pS298-MEK has been shown to localize at periph-
eral adhesion complexes in response to cell adhesion to
fibronectin [45]. Concurrently, we have demonstrated that
tyrosyl phosphorylated PAK1 is localized at peripheral ad-
hesion complexes in response to PRL and is responsible
for proper adhesion turnover, an important process in cell
migration [24]. This is important, as FAK is also localized
at peripheral adhesion complexes and dynamic FAK
localization and phosphorylation is important for proper
adhesion turnover and cell migration (for review [25]).
FAK localization to peripheral cell/matrix adhesions is
dependent on its focal adhesion targeting (FAT) domain
and binding to adhesion proteins paxillin and vinculin
[46, 47]. Paxillin phosphorylation at Y31 and Y118 by
FAK is necessary for cell migration and adhesion turnover
[48–50], however, constitutive tyrosyl phosphorylation of
paxillin impedes cell migration, and dephosphorylation of
FAK by PTP-PEST is required for proper adhesion turn-
over in migrating cells [51]. Furthermore, overexpression
of the dominant negative form of protein phosphatase
LMR-PTP leads to FAK hyperphosphorylation and re-
duced cell motility [38] suggesting that complex regulation
of FAK at adhesion complexes is necessary for proper cell
migration. Phosphorylation of the FAK FAT domain on
S910 and Y925 by ERK2 and Src, respectively, results in re-
duced FAK/paxillin binding and promotes adhesion turn-
over [52, 53]. Furthermore, pS298-MEK/ERK activation in
NIH3T3 cells was shown to induce FAK dephosphoryla-
tion through ERK-mediated FAK S910 phosphorylation
and resulting recruitment of tyrosine phosphatase PTP-
PEST and thereby promote cell motility [30]. In this regard,
PRL-induced tyrosyl phosphorylation of PAK1 and result-
ing adhesion localization could be creating localized PAK1/
MAPK/FAK signaling at adhesion complexes and promot-
ing adhesion turnover during cell migration.
In the present study we demonstrated that tyrosyl
phosphorylation of PAK1 stimulates tumor cell metastasis
in vivo. These data, combined with an animal study
reporting prevention of neoplasia progression into inva-
sive carcinoma in PRL receptor deficient mice [7], suggest
that PRL is involved in the development of metastasis and
tumor progression. Thus, our current data on pTyr-PAK1
regulation of FAK phosphorylation bring insight into the
mechanism of PRL-stimulated motility of breast cancer
cells.
Conclusions
Here we propose a mechanism by which PRL regulates
motility of T47D and TMX2-28 cells through pTyr-
PAK1, MEK/ERK and FAK that integrates our findings
with previous studies (Fig. 8). In response to PRL, FAK
is auto-phosphorylated and PAK1 is tyrosyl phosphory-
lated by JAK2, stimulating PAK1 kinase activity and in-
creasing PAK1 protein-protein binding abilities. We show
that tyrosyl phosphorylated PAK1 phosphorylates MEK at
serine 298, resulting in MEK-mediated ERK1/2 activation.
Activated ERK phosphorylates FAK at S910, leading to
subsequent recruitment of PTP-PEST and dephosphoryla-
tion of Y397-FAK [30]. PRL-dependent down-regulation
of FAK activity may promote focal contact turnover
thereby promoting cell migration. Finally, we demon-
strate for the first time that tyrosyl phosphorylation of
PAK1 by PRL increases breast cancer cell metastasis in
vivo.
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